Head-To-Head Survey: Aptorum Group (NASDAQ:APM) & Cardiol Therapeutics (NASDAQ:CRDL)

Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Risk and Volatility

Aptorum Group has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Insider & Institutional Ownership

3.8% of Aptorum Group shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 64.0% of Aptorum Group shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Aptorum Group and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptorum Group	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aptorum Group and Cardiol Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptorum Group	1	0	0	0	1.00
Cardiol Therapeutics	1	0	2	0	2.33

Cardiol Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 553.85%. Given Cardiol Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Aptorum Group.

Valuation and Earnings

This table compares Aptorum Group and Cardiol Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptorum Group	$430,000.00	12.48	-$1.36 million	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20 million	($0.28)	-4.64

Aptorum Group has higher revenue and earnings than Cardiol Therapeutics.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.